{"created":"2021-03-01T06:20:52.859716+00:00","id":16300,"links":{},"metadata":{"_buckets":{"deposit":"6ae17830-7eba-4eb0-9fa4-e1d71a656cb4"},"_deposit":{"id":"16300","owners":[],"pid":{"revision_id":0,"type":"depid","value":"16300"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00016300","sets":["453:456","471:537:538:1102"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Cytokine Therapy of Renal Cell Cancer"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1998-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"11","bibliographicPageEnd":"692","bibliographicPageStart":"690","bibliographicVolumeNumber":"112","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Metastatic renal cell cancer (RCC) is usually treated with immunotherapy using cytokines because it is a mostly chemoresistant malignancy. These therapies are generally based on interleukin-2 (IL-2) or interferon. However, their response rates were less than 20% and various side effects appeared. In order to improve response rate or reduce side effects, we have tried LAK (lymphokine-activated killer cells) therapy and low dose interferon γ therapy. LAK cells are peripheral blood lymphocytes activated in vitro by exposure to IL-2. LAK therapy was done 10 course for 9 patients in our hospital and the overall respones rate was 60%. On the other hand, low dose interferon γ therapy was done for 10 patients and the side effects were relatively small with the response rate of 10%. These results indicate that immunotherapy using cytokines are useful for metastatic renal cancer and its strategy, including dosage, combination therapy, is still to be investigated.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"103950","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Saito, Toshihiro"}]},{"nameIdentifiers":[{"nameIdentifier":"103951","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Katagiri, Akiyoshi"}]},{"nameIdentifiers":[{"nameIdentifier":"103952","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Tomiya, Yoshihiko"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"斎藤, 俊弘"}],"nameIdentifiers":[{"nameIdentifier":"103947","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"片桐, 明善"}],"nameIdentifiers":[{"nameIdentifier":"103948","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"冨田, 善彦"}],"nameIdentifiers":[{"nameIdentifier":"103949","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-07"}],"displaytype":"detail","filename":"112(11)_690-692.pdf","filesize":[{"value":"523.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"112(11)_690-692.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/16300/files/112(11)_690-692.pdf"},"version_id":"c263e814-f83f-45c3-8360-19abc4b8397f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"renal cell cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"cytokine therapy","subitem_subject_scheme":"Other"},{"subitem_subject":"interferon","subitem_subject_scheme":"Other"},{"subitem_subject":"interleukin-2","subitem_subject_scheme":"Other"},{"subitem_subject":"腎細胞癌","subitem_subject_scheme":"Other"},{"subitem_subject":"サイトカイン治療","subitem_subject_scheme":"Other"},{"subitem_subject":"インターフェロン","subitem_subject_scheme":"Other"},{"subitem_subject":"インターロイキン2","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"6)腎細胞癌に対するサイトカイン治療（シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会）","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"6)腎細胞癌に対するサイトカイン治療（シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会）"},{"subitem_title":"6)腎細胞癌に対するサイトカイン治療（シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会）","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1102"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-02-10"},"publish_date":"2017-02-10","publish_status":"0","recid":"16300","relation_version_is_last":true,"title":["6)腎細胞癌に対するサイトカイン治療（シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会）"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:47:47.757843+00:00"}